{"id":"sar342434","safety":{"commonSideEffects":[{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Nasopharyngitis"},{"rate":null,"effect":"Upper respiratory tract infection"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"APRIL is a TNF superfamily member that promotes B cell survival and plasma cell differentiation, contributing to autoimmune disease pathology. By blocking APRIL, SAR342434 reduces pathogenic B cell responses and autoantibody production. This mechanism is particularly relevant in systemic lupus erythematosus and other B cell-driven autoimmune conditions.","oneSentence":"SAR342434 is a monoclonal antibody that targets and inhibits APRIL (A PRoliferation-Inducing Ligand) to reduce B cell activation and autoimmune responses.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:33:30.268Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Systemic lupus erythematosus (SLE)"}]},"trialDetails":[{"nctId":"NCT03903016","phase":"PHASE1","title":"A Bioequivalence Study Comparing Two Different Strengths Formulations of Insulin Lispro in Patients With Type 1 Diabetes","status":"COMPLETED","sponsor":"Sanofi","startDate":"2019-03-26","conditions":"Type 1 Diabetes","enrollment":90},{"nctId":"NCT02294474","phase":"PHASE3","title":"Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 2 Diabetes Mellitus Also Using Insulin Glargine","status":"COMPLETED","sponsor":"Sanofi","startDate":"2015-01","conditions":"Type 2 Diabetes Mellitus","enrollment":505},{"nctId":"NCT02273180","phase":"PHASE3","title":"Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine","status":"COMPLETED","sponsor":"Sanofi","startDate":"2014-10","conditions":"Type 1 Diabetes Mellitus","enrollment":507},{"nctId":"NCT02603510","phase":"PHASE1","title":"Assessment of the Safety of SAR342434 and Humalog® When Administered as Continuous Subcutaneous Insulin Infusion","status":"COMPLETED","sponsor":"Sanofi","startDate":"2015-11","conditions":"Type 1 Diabetes Mellitus","enrollment":27},{"nctId":"NCT02273258","phase":"PHASE1","title":"A Study to Compare Pharmacokinetics and Pharmacodynamics of SAR342434 to Insulin Lispro in Subjects With Type 1 Diabetes","status":"COMPLETED","sponsor":"Sanofi","startDate":"2013-03","conditions":"Type 1 Diabetes","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":11,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"SAR342434","genericName":"SAR342434","companyName":"Sanofi","companyId":"sanofi","modality":"Small molecule","firstApprovalDate":"","aiSummary":"SAR342434 is a monoclonal antibody that targets and inhibits APRIL (A PRoliferation-Inducing Ligand) to reduce B cell activation and autoimmune responses. Used for Systemic lupus erythematosus (SLE).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}